Trials / Completed
CompletedNCT05863104
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
An Open-label, Uncontrolled, Multicenter Study to Evaluate the Safety, Local Tolerability, Systemic Exposure, and Efficacy of 1% Glycopyrronium Bromide (GPB) Cream in Adolescents With Severe Primary Axillary Hyperhidrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycopyrronium Bromide (GPB) Cream | Application of cream to each axilla |
Timeline
- Start date
- 2023-03-07
- Primary completion
- 2024-03-06
- Completion
- 2024-03-06
- First posted
- 2023-05-17
- Last updated
- 2024-04-04
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05863104. Inclusion in this directory is not an endorsement.